Enzalutamide — Drug Intelligence | 51 EU Trials

Filter these 51 trials by condition, phase, country and more.

Open in Search →

51 Registered trials

26 Recruiting

24 Completed trials

32 Sponsors

25 Countries

Phase III

Phase II

Phase I/II

Phase III: 29 Phase II: 9 Phase I/II: 7 Phase IV: 4 Phase I (FiH): 2

Oversight events:

1 serious breach 27 temporary halts 1 urgent safety measure 7 unexpected events across 7 trials

View oversight register →

Indications tested

Prostate cancer metastatic 14 Prostate cancer 4 Hormone-refractory prostate cancer 2

Sponsors using this IMP

Novartis Pharma AG 8 Merck Sharp & Dohme LLC 6 Pfizer Inc. 5 AstraZeneca AB 2 Cancer Trials Ireland 2 European Organisation For Research And Treatment Of Cancer 2 Region Vaesterbotten 2 UZ Leuven 2 Amgen Inc. 1 Asociacion Instituto De Investigacion Sanitaria Biobizkaia 1 Astellas Pharma Global Development Inc. 1 Bayer AG 1

All trials

51 total

CYPENZA - A prospective cohort trial on antiandrogens influences on the pharmacokinetics of corticosteroids. Pending

2025-520571-66-00 Phase III 1 country Region Vaesterbotten
A Study to Test Inavolisib Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer Recruiting

2025-521327-67-00 Phase II 4 countries F. Hoffmann-La Roche AG
AZD5305 vs Placebo in Men with Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents. Recruiting

2023-504214-30-00 Phase III 11 countries AstraZeneca AB
A clinical trial to learn about the effects of AMO959 given with AAA617 and an androgen receptor pathway inhibitor (ARPI) in adults with PSM… Recruiting

2025-521859-23-00 Phase I/II 4 countries Novartis Pharma AG
A clinical study of opevesostat and standard hormone therapy in people with prostate cancer (MK-5684-004) Recruiting

2023-504957-11-00 Phase III 15 countries Merck Sharp & Dohme LLC
A clinical trial to learn about the effects of DZR123 and JSB462 given together in men with advanced prostate cancer that has stopped respon… Recruiting

2025-521880-10-00 Phase I/II 6 countries Novartis Pharma AG
A Study to Learn About the Investigational Medicine Called Mevrometostat (PF-06821497) in Men With Metastatic Castration-Sensitive Prostate … Recruiting

2024-519369-24-00 Phase III 12 countries Pfizer Inc.
A Phase 1b/2 study of GSK5764227 in combination with Standard of Care (SoC) or other agents in participants with advanced solid tumors Recruiting

2025-522274-37-00 Phase I/II 1 country Glaxosmithkline Research & Development Limited
An open-label study of JSB462 (luxdegalutamide) in combination with abiraterone in adult male patients with metastatic hormone-sensitive pro… Recruiting

2024-520156-22-00 Phase II 7 countries Novartis Pharma AG
A clinical study of ifinatamab deruxtecan to treat metastatic prostate cancer (MK 2400 01A) Recruiting

2024-516036-94-00 Phase I/II 7 countries Merck Sharp & Dohme LLC
Darolutamide and bipolar androgen therapy for mCRPC patients (DaroBAT) Recruiting

2025-521051-23-00 Phase II 1 country Universitaet Muenster
EORTC-2238-GUCG: Improving impact of anti-androgen treatments on patient's daily life and their cancer Recruiting

2023-506817-23-01 Phase III 9 countries European Organisation For Research And Treatment Of Cancer
A Phase 3 Study Comparing BMS-986365 versus Investigator’s Choice of Therapy in Participants with Metastatic Castration-resistant Prostate C… Recruiting

2024-517422-25-00 Phase III 12 countries Celgene Corp.
C2321003: A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men with Metastatic Castration-Resistant… Recruiting

2024-511652-40-00 Phase III 14 countries Pfizer Inc.
Study evaluating whether giving 177Lu-PSMA-617 to men having a spreading prostate cancer which does not respond well to the current standard… Recruiting

2022-502408-57-00 Phase III 6 countries Unicancer
Talazoparib plus Enzalutamide after progression to prior ARPi in Metastatic Prostate Cancer Recruiting

2023-510536-37-00 Phase II 2 countries Fundacion Oncosur
Fractionated stereotactic radiotherapy plus second-generation antiandrogen for oligometastatic patients with castration-resistant prostate c… Recruiting

2023-505024-62-01 Phase II 1 country Instituto de investigación en Oncología radioterápica FEOR (Fundación Española …
A clinical trial comparing a new treatment (MK-5684) to approved medication for advanced prostate cancer after prior hormonal therapy and ch… Recruiting

2023-504899-25-00 Phase III 14 countries Merck Sharp & Dohme LLC
A Randomised study comparing Lutetium-177 versus Apalutamide/Enzalutamide/Abiraterone, in metastatic Hormon Sensitive Prostate Cancer in PSM… Recruiting

2022-500570-33-00 Phase III 1 country Region Västerbotten; Umea University
Shortened 12 months duration of androgen receptor signalling agent in combination with androgen deprivation therapy in patients with low-vol… Recruiting

2023-506698-36-00 Phase III 1 country Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Evaluation of the impact of metastasis-directed therapy in patients with castration-refractory prostate cancer and a maximum of 5 progressiv… Recruiting

2022-502254-13-00 Phase III 1 country UZ Leuven
Metastasis-directed therapy, whether or not in combination with hormone therapy, in patients with prostate cancer recurrence after initial t… Recruiting

2022-502373-42-00 Phase III 1 country UZ Leuven
DZR123 (CPI-0209) in Patients with Advanced Solid Tumors and Lymphomas Recruiting

2023-508002-20-00 Phase I (FiH) 4 countries Novartis Pharma AG
RAndomized, open label, multicenter study of Docetaxel versus an Androgen Receptor-targeted agent (abiraterone orenzalutamide) as first-line… Recruiting

2024-518623-30-00 Phase IV 1 country Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Showing 1–24 of 51 trials

← All drugs A–Z